Drug intelligence / Profile preview

DE-108

Development stage: Unknown
Lead developer: Santen Pharmaceutical
Modality: Small Molecules
Administration: Ophthalmic

Overview

DE-108 is an ophthalmic solution developed by Santen Pharmaceutical Co., Ltd. It is being investigated for its superior efficacy and safety in perioperative bacteria eradication in patients scheduled for cataract surgery. The drug is administered as one drop, three times daily, for three days prior to and fourteen days following cataract surgery. It is currently in Phase III clinical trials, where it is being compared to Levofloxacin 0.5% ophthalmic solution.

Targets

Topo IV (Bacterial Topoisomerase IV)GyrA (DNA gyrase subunit A)

Beyond the preview

Go deeper on DE-108.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DE-108.

Explore the full profile